ClinicalTrials.gg

TargetBeta

PIK3CA

phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha · also PI3K · Phosphatidylinositol 3-kinase family

14 programs in company-led studies act on PIK3CA, from 14 companies: 4 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (13 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
AlpelisibruleNovartisphase 43711 running–ChEMBL
inavolisibruleHoffmann-La Rochephase 32017 running–ChEMBL
tersolisibEli Lillyphase 3104 running–a judged reading
gedatolisibrulePfizerphase 393 runningMTOR, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R5ChEMBL
PI3K-alpha Inhibitor JS105ruleRisen (Suzhou) Pharma Techphase 311 running–NCIt
serabelisibruleTakedaphase 2112 running–ChEMBL
risovalisibruleHaihe Biopharmaphase 242 running–NCIt
zovegalisibruleRelay Therapeuticsphase 222 running–NCIt
paxalisibruleKazia Therapeuticsphase 241 runningPIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R5ChEMBL
Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rulePikavation Therapeuticsphase 211 running–NCIt
Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636ruleEnsem Therapeuticsphase 211 running–NCIt
Mutant-selective PI3K-alpha Inhibitor RGT-490ruleRegor Pharmaceuticalsphase 111 running–NCIt
PI3Ka H1047R Mutant Selective Inhibitor CGT6297ruleCogent Biosciencesphase 111 running–NCIt
RAS/PI3K-alpha Inhibitor VVD-159642ruleBayerphase 111 running–NCIt

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.